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Editorial: Synthetic Microbiology as a Source of New Enterprises and Job Creation
Breaking the state-of-the-art in the chemical industry
with new-to-Nature products via synthetic microbiology
Laura Martinelli1 and Pablo I. Nikel2
1IN SRL, 33100 Udine, Italy.
2The Novo Nordisk Foundation Center for
Biosustainability, Technical University of Denmark, 2800
Lyngby, Denmark.
Scientists study the world as it is; engineers create the
world that has never been Theodore von Karman (1881–
1963)
The core tenet of synthetic biology is applying engineer-
ing principles such as standardization, modularity and
rational design to accelerate the design-build-test loop
aimed at reprogramming biological systems by endowing
them with novel tasks (Endy, 2005). This circumstance
has been broadly exploited to engineer whole-cell cata-
lysts able to produce a plethora of added-value mole-
cules (Lee et al., 2012; Nielsen and Keasling, 2016; de
Lorenzo et al., 2018). Accordingly, the last few years
have witnessed a steady increase in the number and
type of molecules that can be accessed through rational
modiﬁcation of biocatalysts (Renata et al., 2015; Sman-
ski et al., 2016; Arnold, 2018) – after all, and as recently
pointed out by Prather (2019), biology is a most remark-
able and versatile chemist. Yet, only a very limited
number of structurally simple metabolites (e.g. the diols
1,4-butanediol and 1,3-propanediol) and a few natural
active compounds (e.g. artemisinin) have found their
way towards industrial-scale production (Calero and
Nikel, 2019). Indeed, commercially relevant bioprocesses
account for a mere 3.5% of the total production volume
of commodity and specialty chemicals nowadays (Camp-
bell et al., 2017). Accessing new-to-Nature products
through synthetic microbiology is not only desirable, but
also an actual necessity in a rapidly changing world in
which the access to natural, fossil-based resources is
becoming critically limited.
The European chemical industry can deﬁnitely beneﬁt
from the purposeful redesign of the ‘biochemical palate’
of bacteria to access products that are difﬁcult to obtain
otherwise. Bringing non-biological chemical elements
into the biochemical agenda of cell factories, e.g. halo-
gens and silicon (O’Hagan and Deng, 2015; Kan et al.,
2016), has the potential of actually revolutionizing biopro-
duction by multiplying the catalytic power of whole-cell
biocatalysts. The biological incorporation of ﬂuorine (F)
into organic molecules is a particularly fascinating possi-
bility to break the state-of-the-art in the chemical indus-
try. Current technologies for addition of F into organic
structures rely on chemical reactions derived from non-
renewable sources, and often require corrosive reagents
(Harsanyi and Sandford, 2015) – with the corresponding
negative environmental impact that they cause. The
expansion of the market of ﬂuorinated molecules in the
pharmaceutical [ca. 25% of the drugs currently licensed
contain some type of ﬂuorinated structure (Wang et al.,
2014)], agriculture and material sectors worldwide
(Fig. 1) is not matched by the development of more efﬁ-
cient, safer and milder technologies needed for their pro-
duction. The global market demand of ﬂuorochemicals is
expected to reach >5300 kiloTons by 2024, expanding
at a compound annual growth rate of 4.3% during the
period 2014–2024. Because of the broad applications of
ﬂuoropolymers in essentially all industrial sectors, these
ﬂuorinated compounds represent >50% of the increase
in the overall demand of ﬂuorochemicals (Fig. 1).
Indeed, the global ﬂuoropolymer market was valued at
4700 M€ in 2015, and is expected to reach >7800 M€ by
2022, registering a compound annual growth rate of
7.7% from 2016 to 2022. The Asia–Paciﬁc axis
accounted for a >45% share of the total revenue of ﬂuo-
rochemicals in 2015, followed by North America and
then Europe. Moreover, developing countries in the
Asia–Paciﬁc region are anticipated to register steady
growth rates in their individual economies owing to the
increasing growth of the overall, worldwide economy.
What is the role of synthetic microbiology in tackling
these issues, and positioning Europe as a leader region
for innovation towards a true bioeconomy based in new-
to-Nature products?
As of today, there are no alternatives to traditional F
chemistry available for production, and classical chem-
istry approaches have largely failed to provide an eco-
nomically and environmentally sustainable route to
ﬂuorochemicals. Against this background, the EU project
SinFonia (Synthetic biology-guided engineering of
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Pseudomonas putida for bioﬂuorination), coordinated by
P.I.N., brings together 13 partners [including 5 small-to-
medium enterprises (SMEs) and a large multinational
company] with the common goal of providing a bio-
based solution for the production of ﬂuorochemicals
(Fig. 2). P. putida is the bacterial chassis of choice to
engineer trans-metabolisms for the production of this sort
of molecules (Nikel and de Lorenzo, 2018), which
require a complex biochemistry that few (if any) bacteria
can support. The scope of SinFonia, a Research and
Innovation Action embedded in the BIOTEC-03-
2018―Synthetic biology to expand diversity of nature’s
chemical production call, will set the stage for a future
economically, ecologically and societally sustainable
value chain for the production of novel, bio-based ﬂuo-
ropolymers from renewable substrates. In particular, the
markets addressed in the domain of ﬂuoropolymer appli-
cations are key for some of the most vital value chains
for Europe competitiveness, i.e. electronics, automotive
and textiles. Synthetic microbiology lays at the core tech-
nologies to be implemented in SinFonia to enable novel
biochemistries in the platform strain KT2440.
Meanwhile, what is the situation of biotechnology-based
companies in Europe to broaden their scope through syn-
thetic microbiology? As recently indicated by Vilanova and
Porcar (2019), bio-based production keeps growing in
number and revenues in the EU, and the market,
traditionally controlled by a handful of big chemical and
pharma companies, is expanding through the activities of
SMEs that developed creative business models based on
research and development as the pillar of competitive-
ness. UK and Germany form a powerful hub of biotechnol-
ogy companies – in 2017, around 30% of all venture
capital in Europe went to activities based in UK. Scandina-
vian countries are likewise strong promoters of innovation
in the industrial sector. The so-called Medicon Valley is a
leading international life sciences cluster in Europe, span-
ning the Greater Copenhagen region of eastern Denmark
and southern Sweden and composed by a large number
of life science companies and research institutions. Life
science companies in Medicon Valley employed 41 300
individuals in 2015, registering an annual increase in this
trend of around 4%. Denmark leads the way in biotechnol-
ogy-oriented companies: in 2016, for instance, the Danish
biotechnology sector was classiﬁed as the best in Europe,
only behind United States and Singapore globally (Mor-
rison and L€ahteenm€aki, 2017). Research and innovation
in the Scandinavian region (and in Denmark in particular)
is fuelled by >2000 M€ of tax contribution. Technology
transfer is also an important part of the region-wide initia-
tive: the number of patent applications submitted to the
European Patent Ofﬁce by Danish life science companies
rose 16% between 2008 and 2016. Taken together, these
ﬁgures indicate that the ground for novel, biotechnology-
based (and synthetic biology-inspired) entrepreneur
endeavours in the Scandinavian region is ﬂourishing. EU-
Fig. 1. Global market of ﬂuorochemicals and classiﬁcation and
applications of ﬂuoropolymers. The current trends indicate a steady
increase in the global market demand for diverse ﬂuorochemicals
and, in particular, ﬂuoropolymers. As indicated in the inset, these
molecules have countless applications in almost every sector of the
industry. Thus far, no bio-based technologies were available for the
production of ﬂuorochemicals.
Fig. 2. Synthetic microbiology as the enabling technology for the
production of new-to-Nature products. The EU-funded project SinFo-
nia (Synthetic biology-guided engineering of Pseudomonas putida
for bioﬂuorination) is a transnational effort aimed at developing novel
biochemistries in the platform strain P. putida KT2440. Synthetic
microbiology will bring non-biological elements, such as halogens,
into the core metabolism of this bacterium for the sake of whole-cell
catalysis, resulting in new-to-Nature products containing ﬂuorine.
The ultimate outcomes of the project include the creation of bio-
based enterprises and jobs towards a sustainable EU bioeconomy.
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funded research and innovation actions, which bring
together diverse academic expertise as well as technical
and industrial known-how, will be major facilitators for the
much sought academia-to-industry transition.
The technology transfer to the industrial sector could
take place in many ways, but there are mainly two mod-
els of value chain development of bio-based processes.
The ﬁrst model is absorption, where parts or all of the
value chain of synthetic microbiology are used within a
sector-speciﬁc company. This approach implies that an
acquisition of facilities, human resources and knowledge
is pursued by the company that is aiming to bring the
new product(s) and/or process(es) to the market. This
also implies either a profound organizational change
(usually an extremely complex process in a company –
the success of which cannot be taken for granted), or
the acquisition of an entire new company (basically an
SME). Selling-in, in contrast, does not require a transfor-
mational change: a product is designed in a company
and sold into the production step of a speciﬁc sector.
The challenge here is to properly address the question
‘what is to be sold and to whom’. The two strategies can
be implemented depending on the dynamics of the
market targeted – and, again, a fertile ground for the
development of spin-offs and drop-in companies is a
pre-requisite for the smooth transition of knowledge-
based technologies into actual applications in the indus-
trial sector. The adoption of one model or the other will
have a profound inﬂuence on this rapidly growing ﬁeld,
shaping the value chain ecosystem that will emerge in
the next 20–30 years. The ecosystems resulting from
the different options are substantially different; in the ﬁrst
case (absorption), it will be the multinationals to lead the
change, with spin-offs and start-ups providing the seeds
of innovation without ever growing to a fully mature
stage. In the second scenario (selling-in), it is more likely
that a more diverse ecosystem will emerge, sustaining
new companies to grow to a mature stage. Currently in
Europe, the pharmaceutical industry has shown prefer-
ence for the absorption model, while the chemical indus-
try is still waiting to see the ﬁrst large batch of bio-based
commodities to be developed – and which of the options
will be preferred in this case is still a matter of debate.
Considering the lessons learnt from the ﬁrst wave of
synthetic biology-related products and the public debate
associated, it is likely that a mixed scenario will emerge,
and this would be also be preferable and more sustain-
able in the long run.
One way or the other, some long-sought goals for sus-
tainable bio-based production of chemical building blocks
are expected to be attained in the near future. Synthetic
microbiology will not only underpin these developments,
but it will also become increasingly pervasive throughout
the full spectrum of research and development of new-
to-Nature, added-value molecules – tackling some
issues that have been almost neglected in the ﬁeld, such
scaling up of synthetic biology constructs and processes
(de Lorenzo and Couto, 2019). Combined with the cre-
ation of jobs and enterprises, synthetic microbiology
holds the promise to decisively contribute to the much-
wanted shift from a petrochemical-based to a bio-based
society and economy in Europe. Wide public acceptance
will be essential in this respect; at the same time, a
diverse ecosystem supported by a dynamic community
of both SMEs and large companies is more likely to sus-
tain European competitiveness.
Considering the critical point of public acceptance of dis-
ruptive technologies and science innovation, and in the
particular case of synthetic microbiology, lessons can be
learnt from the past, when we saw how agricultural
biotechnology had met reluctance or rejection among the
public. With the new technologies brought about by syn-
thetic biology, the question many people ask themselves
is whether history will repeat itself, i.e. whether there will
be public controversy when the resulting products start to
be commercialized (Torgersen, 2009). The commitment
of the scientiﬁc community to divulge a correct and effec-
tive communication on the matter is vital in this sense.
For such innovations to boost European industry competi-
tiveness at the current stage of development, it will be
essential to pursue the debate on (i) what a synthetic (mi-
cro)biology actually is, (ii) where does its value come
from, (iii) what is to be sold and to whom (i.e. future value
chains) and (iv) the standardization of such products (en-
suring market reproducibility of the new product). Such a
case-by-case debate should be started already at very
low TRLs (technology readiness levels) and should
include a coherent policy for the protection of knowledge
(Chiarotti, Portaluri and Martinelli, unpublished data).
From a broader perspective, the impact on synthetic (mi-
cro)biology on the future of jobs in Europe is an impor-
tant topic that raises many interesting questions, e.g. will
this new wave create new and qualiﬁed jobs?, or how
existing job proﬁles will be affected? This kind of reason-
ing is strictly interlinked with both the model of adoption
of synthetic biology products by the industry and the
impact that such products will have on the market. Some
job proﬁles might disappear, some might require sub-
stantial re-learning, some others will be new, including
completely different skills and background knowledge.
The extent and speed of this transformation is a function
of business adoption, government and education – and
thus a function of human decisions (Gulbranson, 2018).
The scenario we have drafted implicitly considers
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technology development as a social process, over which
many different factors play a key role. The outcome can
only be forecasted by taking into consideration an inte-
grated and wider perspective, e.g. the Research
Responsible Innovation (Owen et al., 2013). Emerging in
the last decade, this approach dares to take into account
the difﬁcult dilemma between thinking and reasoning on
the future trajectories that an innovation can take, how
to control it, and the need to allow enough freedom of
movement for an innovation to unfold. Far from trying to
impose limitations, we believe that considering a per-
spective of inclusiveness, anticipation and responsive-
ness to the possible impacts of synthetic microbiology
by the relevant stakeholders could effectively contribute
to its success as a socially positive transformation and
value creation at the same time. In fact, all the scenarios
discussed in this article lead to an emerging picture in
EU, where the advances in synthetic (micro)biology
approaches to chemistry is paired with a likewise impact-
ful growth in the creation of new enterprises (or new
activities in established enterprises) and the creation of
employment – building into an authentic circular, bio-
based economy.
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